Table 3 Associations between MTC02 expression results and ERG positive prostate cancer phenotype

All cancers

3.35

1.8

12.2

33.8

52.2

PSA preoperative

<4

451

2.66

11.97

32.59

52.77

0.9613

4-10

2.03

1.73

12.03

34.12

52.12

10-20

604

1.66

12.75

33.44

52.15

>20

218

1.83

13.3

35.78

49.08

Tumor stage

pT2

1.980

1.92

11.31

34.55

52.22

0.5463

pT3a

902

1.77

13.86

33.81

50.55

pT3b

427

1.64

12.41

30.68

55.27

pT4

22

0

18.18

36.36

45.45

Gleason grade

≤3 + 3

745

3.36

10.07

36.64

49.93

0.008

3 + 4

1.98

1.26

12.32

33.01

53.41

4 + 3

485

2.06

14.85

33.81

49.28

≥4 + 4

114

0.88

13.16

32.46

53.51

Lymph node metastasis

N0

1.9

1.63

12.2

34.56

51.6

0.7185

N+

192

1.04

14.58

32.81

51.56

Surgical margin

Negative

2.62

1.83

12.48

33.73

51.96

0.825

Positive

670

1.94

11.19

34.63

52.24